Nabriva Therapeutics

Nabriva Therapeutics Plc is a biopharmaceutical company, which engages in the research, development, and commercialization of novel anti-infective agents to treat serious infections. Its product pipeline includes Lefamulin, CONTEPO, and BC-7013. The company was founded in October 2005 and is headquartered in Dublin, Ireland.

Earnings data Q1 2023

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Nabriva Therapeutics Plc is a biopharmaceutical company, which engages in the commercialization and development of novel anti-infective agents to treat infections. The company was founded in October 2005 and is headquartered in Dublin, Ireland.

Nabriva Therapeutics Plc (NASDAQ: NBRV) entered an agreement with Vizient to offer Xenleta as a contracted product to Vizient's Pharmacy Network Program. Xenleta is indicated for community-acquired bacterial pneumonia (CABP).

Nabriva Therapeutics, Vizient Inks Xenleta Distribution Pact

The stock price of Nabriva Therapeutics PLC (NASDAQ: NBRV) increased by over 3% pre-market today. This is why it happened.

NBRV Stock: Why It Increased Today

- Expands access to XENLETA for hospitalized patients with Community Acquired Bacterial Pneumonia (CABP) - Expands access to XENLETA for hospitalized patients with Community Acquired Bacterial Pneumonia (CABP)

Nabriva and Vizient Enter into Agreement to Make XENLETA® (lefamulin) Available to Vizient's Pharmacy Network Program

DUBLIN, Ireland and FORT WASHINGTON, Pa., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, announced today that its partner, Sumitomo Pharmaceuticals (Suzhou) Co., Ltd. has received approval to market oral and intravenous (IV) formulations of XENLETA® (lefamulin) for the treatment of community-acquired pneumonia (CAP) in adults in Taiwan.

Lefamulin Receives Approval in Taiwan for Treatment of Community-Acquired Pneumonia

DUBLIN, Ireland, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it has granted non-statutory stock options to purchase an aggregate of 32,130 ordinary shares of Nabriva Therapeutics as an inducement to three newly-hired employees. These grants were awarded pursuant to the Nasdaq inducement grant exception as a component of new hire employment compensation.

Nabriva Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

DUBLIN, Ireland and FORT WASHINGTON, Pa., Aug. 31, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that Ted Schroeder, Chief Executive Officer at Nabriva, will provide a company overview and business update at the H.C. Wainwright 23rd Annual Virtual Global Investment Conference. The presentation will be available on-demand starting Monday, September 13, at 7:00 A.M. (ET).

Nabriva Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

Nabriva Therapeutics plc (NBRV) CEO Ted Schroeder on Q2 2021 Results - Earnings Call Transcript

The stock price of Nabriva Therapeutics PLC (NASDAQ: NBRV) increased by over 15% pre-market. This is why it happened.

NBRV Stock Price Increases Over 15% Pre-Market: Why It Happened

-Revenues of $8.2 million driven by launch of own National Drug Code (NDC) for SIVEXTRO-

Nabriva Therapeutics Reports Second Quarter 2021 Financial Results and Provides a Corporate Update

DUBLIN, Ireland, July 22, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it will report its second quarter financial results along with recent company highlights after the close of the U.S. financial markets on Thursday, August 5, 2021. Nabriva's management will host a conference call at 4:30 p.m. ET to discuss the financial results and recent corporate highlights.

Nabriva Therapeutics to Report Second Quarter 2021 Financial Results and Recent Corporate Highlights on August 5, 2021

Nabriva Therapeutics AG (NBRV) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Down 15.7% in 4 Weeks, Here's Why You Should You Buy the Dip in Nabriva Therapeutics AG (NBRV)

- Principal Repayments Delayed At Least Until January 1, 2022

Nabriva Agrees to Extension of Principal Debt Repayments Under Existing Loan Agreement with Hercules Capital

DUBLIN, Ireland and FORT WASHINGTON, Pa., June 02, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, announced today that Dr. Mark Corrigan and Lisa Dalton have joined the Company's Board of Directors. In addition, after many years of service Dr. George Talbot has notified the company of his decision not to stand for re-election to the Board of Directors. Dr. Talbot is expected to continue his service on the Board of Directors until the conclusion of his term at the 2021 Annual General Meeting of Shareholders.

Nabriva Announces Changes to its Board of Directors

Nabriva Therapeutics PLC – ADR (NASDAQ:NBRV) shares are trading higher by 48% at $2.19 Wednesday morning after the company, and Sinovant Sciences, announced topline results from the Phase 3 trial of lefamulin in Chinese adults with community-acquired bacterial pneumonia. Nabriva Therapeutics is a clinical-stage biopharmaceutical company.

Why Nabriva Therapeutics Stock Is Surging Today

Nabriva Therapeutics (NASDAQ: NBRV) and its collaborating partner in China, Sinovant Sciences, have announced positive topline results from Sinovant's Phase 3 bridging study evaluating lefamulin in Chinese adults with community-acquired bacterial pneumonia (CABP). Lefamulin met the primary endpoint of non-inferiority versus moxifloxacin, a broad-spectrum antibiotic for Investigator Assessment of Clinical Response at Test of Cure (IACR-TOC).

Nabriva Therapeutics Stock Gains On Positive Lefamulin Data In CABP Patients In China

The stock price of Nabriva Therapeutics PLC (NASDAQ: NBRV) increased by over 60% pre-market. This is why it happened.

NBRV Stock Price: Over 60% Increase Pre-Market Explanation

HONG KONG, SHANGHAI, China, SUZHOU, China and DUBLIN, Ireland, May 25, 2021 (GLOBE NEWSWIRE) -- Sinovant Sciences, a Chinese biopharmaceutical company dedicated to conducting innovative biomedical R&D in China, and Nabriva Therapeutics (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced positive topline results from Sinovant's Phase 3 bridging study of lefamulin in Chinese adults with community acquired bacterial pneumonia (CABP).

Sinovant Sciences and Nabriva Therapeutics Announce Positive Topline Results from Phase 3 Trial of Lefamulin in Chinese Adults with Community Acquired Bacterial Pneumonia (CABP)

DUBLIN, Ireland and KING OF PRUSSIA, Pa., May 21, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that Ted Schroeder, Chief Executive Offer at Nabriva, will provide a company overview and business update at the Jefferies Virtual Healthcare Conference on Thursday, June 3, at 2:30 p.m. ET.

Nabriva Therapeutics to Present at the Jefferies Virtual Healthcare Conference

Nabriva Therapeutics plc (NBRV) CEO Ted Schroeder on Q1 2021 Results - Earnings Call Transcript

-First quarter of full complement of 60 sales representatives further expanding the reach of XENLETA ® (lefamulin) and SIVEXTRO ® (tedizolid phosphate) in the community-

Nabriva Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate Updates

DUBLIN, Ireland, April 29, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it will report its first quarter financial results along with recent company highlights after the close of the U.S. financial markets on Thursday, May 6, 2021. Nabriva's management will host a conference call at 4:30 p.m. ET to discuss the financial results and recent corporate highlights.

Nabriva Therapeutics to Report First Quarter 2021 Financial Results and Recent Corporate Highlights on May 6, 2021

- SIVEXTRO now available under Nabriva's National Drug Code

Nabriva Commences Exclusive Distribution of SIVEXTRO® (tedizolid phosphate) in the U.S.

Adobe

Cardiff Oncology

Kinsale Capital Group

Veeva Systems

Want to try an out-of-the-box approach? Tap five stocks with increasing P/E ratios.

Rising P/E: An Overlooked Strategy to Pick Winning Stocks

Yext

Forget undervalued stocks, play these top-ranked stocks with rising P/E.

5 Best Stocks With Rising P/E to Buy for Solid Returns

DUBLIN, Ireland and KING OF PRUSSIA, Pa., April 01, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that Ted Schroeder, Chief Executive Offer at Nabriva, will provide a company overview and business update at the 20th Annual Needham Virtual Healthcare Conference on Thursday, April 15, at 2:15p.m. ET.

News for Nabriva Therapeutics Stock (NBRV)